Published in Drug Week, December 2nd, 2005
Based on the outcome of the meeting, the company believes its planned phase III clinical trial design and its regulatory strategy for Amoxicillin Pulsys for adults and adolescents with pharyngitis/tonsillitis were acceptable to the FDA. Advancis is now ready to begin the phase III trial and expects to start enrolling patients later this month.
"We are very pleased to be moving forward with our phase III trial program for Amoxicillin...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.